Home > Insider Trading > Filing (0001209191-14-065103)

Filing Details

Accession Number:: 0001209191-14-065103
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2014-10-28 17:03:32
Reporting Period:: 2014-10-22

Filing Date:: 2014-10-28
Accepted Time:: 2014-10-28 17:03:32
Original Submission Date:: 2014-10-24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1505512	Regulus Therapeutics Inc.	RGLS	Pharmaceutical Preparations (2834)	264738379

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
874015	Isis Pharmaceuticals Inc	2855 Gazelle Court Carlsbad CA 92010		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-10-22	9,283	$12.18	6,899,517	No	4	S	Direct
Common Stock	Disposition	2014-10-22	15,791	$12.83	6,883,726	No	4	S	Direct
Common Stock	Disposition	2014-10-22	57,753	$13.91	6,825,973	No	4	S	Direct
Common Stock	Disposition	2014-10-22	15,156	$14.67	6,810,817	No	4	S	Direct
Common Stock	Disposition	2014-10-22	11,376	$16.59	6,799,441	No	4	S	Direct
Common Stock	Disposition	2014-10-22	175	$17.11	6,799,266	No	4	S	Direct
Common Stock	Disposition	2014-10-23	1,200	$13.94	6,798,066	No	4	S	Direct
Common Stock	Disposition	2014-10-23	450	$14.90	6,797,616	No	4	S	Direct
Common Stock	Disposition	2014-10-23	50	$15.45	6,797,566	No	4	S	Direct
Common Stock	Disposition	2014-10-24	1,054	$14.63	6,796,512	No	4	S	Direct
Common Stock	Disposition	2014-10-24	350	$15.50	6,796,162	No	4	S	Direct
Common Stock	Disposition	2014-10-24	446	$16.29	6,795,716	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2014.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.47 to $12.47 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The shares are held directly by Isis Pharmaceuticals, Inc. Ms. Parshall is an officer and director of Isis and therefore may be deemed to have voting or investment power over the shares beneficially owned by Isis. Ms. Parshall disclaims beneficial ownership over the shares beneficially owned by Isis, except to the extent of her proportionate pecuniary interest therein as a stockholder of Isis.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $13.44 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.47 to $14.47 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $15.27 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $17.00 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.30 to $14.27 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.42 to $15.30 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $15.02 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.23 to $15.71 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This Form 4 is being amended to itemize the sales prices which were not available at the time the Form 4 was originally filed. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.31 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.